Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Daratumumab in Chinese Patients with Multiple Myeloma
NCT04121260Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2019
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoints: Adverse Events and Serious Adverse Events up to 2 years, Maximum Observed Serum Concentration and 1 more. Started Dec 2019; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04121260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121260.